WCG Wealth Advisors LLC Sells 98 Shares of Novo Nordisk A/S (NYSE:NVO)

WCG Wealth Advisors LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.9% in the second quarter, Holdings Channel.com reports. The firm owned 10,830 shares of the company’s stock after selling 98 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,546,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S during the first quarter worth $25,000. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S during the 2nd quarter worth about $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $26,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $26,000. Finally, Gilliland Jeter Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Argus lifted their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $145.17.

Novo Nordisk A/S Trading Up 2.2 %

NVO stock opened at $134.90 on Friday. Novo Nordisk A/S has a one year low of $86.96 and a one year high of $148.15. The stock has a market cap of $605.37 billion, a price-to-earnings ratio of 46.52, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The company has a fifty day moving average price of $133.43 and a two-hundred day moving average price of $133.20. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). The company had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Equities analysts anticipate that Novo Nordisk A/S will post 3.11 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.83%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.